# Desflurane

## Suprane 240mL

##### 

| Title              | Content                                                                                                                                                                                                                                               |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | ESUP                                                                                                                                                                                                                                                  |
| Indications        | Inhalation agent for induction & maintenance of general anesth.                                                                                                                                                                                       |
| Dosing             | Induction: Adult Initially 3%， increased by 0.5-1% every 2-3 breaths. Inspired concentration of 4-11% produces surgical anesthesia in 2-4 minutes. Maintenance: Adult whether mix nitrous oxide or not， 2.5-8.5% Suprane. Children 5.2-10% Suprane. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                         |
| Contraindications  | Patient in whom general anaesth is contraindicated. Sensitivity to halogenated agents. Genetic susceptibility to malignant hyperthermia.                                                                                                              |
| Adverse Effects    | Dose-dependent hypotension & respiratory depression. Cough， breath holding， salivation， apnoea & laryngospasm. Post-op nausea & vomiting. Transient increase of WBC count， malignant hyperthermia.                                                |
| Pregnancy          | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                         |

